Matinas BioPharma Holdings (MTNB) Net Cash Flow (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Net Cash Flow of -$1.6 million for Q1 2026, down 344.72% year-over-year from $654211.1 in Q1 2025, and down 11.49% quarter-over-quarter from -$1.4 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Net Cash Flow (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Net Cash Flow for 14 consecutive years, with -$1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 344.72% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$4.8 million (down 182.8% YoY), while the FY2025 annual figure was -$3.3 million, down 231.56% from the prior year.
- Net Cash Flow fell to -$1.6 million in Q1 2026 per MTNB's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $6.1 million in Q3 2024 and bottomed at -$8.9 million in Q2 2022.
- Historically, Net Cash Flow has averaged -$1.1 million across 5 years, with a median of -$1.4 million in 2025.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 529.34% — and 2024, when it soared 282.22%.
- Matinas BioPharma Holdings' Net Cash Flow stood at -$4.3 million in 2022, then soared by 62.72% to -$1.6 million in 2023, then slumped by 85.86% to -$3.0 million in 2024, then jumped by 52.31% to -$1.4 million in 2025, then slipped by 11.49% to -$1.6 million in 2026.
- Business Quant data shows MTNB's Net Cash Flow at -$1.6 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - | 225.59 Mn |
| 10 | Matinas BioPharma Holdings | 1.18 Mn | 373,504.72 | - | -1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.84 Mn |
| Jun 30, 2026 | -1.84 Mn |
| Mar 31, 2026 | -1.60 Mn |
| Mar 31, 2026 | -1.60 Mn |
| Dec 31, 2025 | -1.44 Mn |
| Dec 31, 2025 | -1.44 Mn |
| Sep 30, 2025 | -1.41 Mn |
| Sep 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -399,000.00 |
| Jun 30, 2025 | -399,000.00 |
| Mar 31, 2025 | -360,000.00 |
| Mar 31, 2025 | -360,000.00 |
| Dec 31, 2024 | -3.01 Mn |
| Dec 31, 2024 | -3.01 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | -3.72 Mn |
| Mar 31, 2024 | -3.72 Mn |